Assessment of Genetic and Immunological Factors Associated with Hepatitis C Infection in Saudi Hemodialysis Patients


The association of human leukocyte antigen (HLA) genotype and hepatitis C virus (HCV) infection has been reported in many populations. In addition, the HLA genotype distribution has been found to differ according to ethnicity. Currently, there are no published data concerning this relationship in the Saudi population. Therefore, the primary objective of this study was to determine the relationship between HLA genotype and HCV infection in a group of haemodialysis patients in a tertiary hospital in the Eastern Province of Saudi Arabia. A total of 152 haemodialysis patients and 160 controls were enrolled in the study. The patient group included 91 males and 61 females with a mean age of 48 years, who had been on haemodialysis for a period of 6 months to five years. The control group was randomly selected from donors attending the blood bank and included 155 males and five females with a mean age of 38 years. Of the patient group, 27 (17.8%) were found to have HCV antibodies by EIA. The seropositivity was confirmed by RIBA and by RT-PCR. The average viral load was 15 × 103 HCV RNA per 10 μl of plasma. The predominant HCV genotype was found to be genotype 4. HLA-class I and HLA class II were screened in 27 HCV-positive patients and in 30 age and sex matched controls by polymerase chain reaction/sequence specific primers (PCR/SSP) method. Measurements of cytokines Interleukin-2, 10, IFN-γ and TNFα showed that IL-2 level was 17.65 - 20.3 pg/l; IFN-γ was 22.15 - 41.1 pg/l; TNF-α was 2.5 - 5.6 pg/mL and IL-10 was 10.7 - 14.8 pg/mL. Measurement of CD markers showed the following: CD3 cells were measured. There was no correlation between infection with HCV and HLA type, cytokines levels and levels of different cell populations. CD markers are similar in the HCV-positive and HCV-negative hemodialysis patients. Further analysis and comparisons are needed, especially between the cytokines and CD markers in the hemodialysis patients and control groups.

Share and Cite:

Alzahrani, A. , Obeid, O. , Alali, A. , Al-Mueilo, S. , Al-Sheihk, Y. and Ulhasan, M. (2014) Assessment of Genetic and Immunological Factors Associated with Hepatitis C Infection in Saudi Hemodialysis Patients. Journal of Biosciences and Medicines, 2, 51-57. doi: 10.4236/jbm.2014.21006.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Jondeby, M.S., De-Los Santos, G.G., Al-Ghamdi, A.M., Al-Hawas, F.A., Mousa, D.H., Al-Sulaiman, M.H. and Al-Khader, A.A. (2001) Caring for Hemodialysis Patients in Saudi Arabia. Past, Present and Future. Saudi Medical Journal, 22, 199-204.
[2] Qadi, A.A., Tamim, H., Ameen, G., Bu-Ali, A., Al-Arrayed, S., Fawaz, N.A. and Almawi, W.Y. (2004) Hepatitis B and Hepatitis C Virus Prevalence among Dialysis Patients in Bahrain and Saudi Arabia: A Survey by Serologic and Molecular Methods. American Journal of Infection Control, 32, 493-495.
[3] Gilli, P., Moretti, M., Soffritti, S. and Menini, C. (1990) Anti-HCV Positive in Dialysis Units? Lancet, 336, 243-244.
[4] Willems, M., de Jong, G., Moshage, H., Verresen, L., Goubau, P., Desmyter, J. and Yap, S.H. (1991). Surrogate Markers Are Not Useful for Identification of HCV Carriers in Chronic Hemodialysis Patients. Journal of Medical Virology, 35, 303-306.
[5] Sakamoto, N., Enomoto, N., Marumo, F. and Sato, C. (1993). Prevalence of Hepatitis C Virus Infection among Long-Term Hemodialysis Patients: Detection of Hepatitis C Virus RNA in Plasma. Journal of Medical Virology, 39, 11-15.
[6] Saeed, A.A., Fairclough, D., Al-Admawi, A.M., Bacchus, R., Al-Raseed, A.M., et al. (1990) Hepatitis C Virus in Saudi Arabia: A Preliminary Survey. Saudi Medical Journal, 11, 331-332.
[7] Mitwalli, A., Al-Mohaya, S., Al-Wakeel, J., El Gamal, H., Rotimi, V., et al. (1992) Hepatitis C in Chronic Renal Failure Patients. American Journal of Nephrology, 12, 288-291.
[8] Ayoola, E.A., Huraib, S., Arif, M., Al-Faleh, F.Z., Al-Rashed, R., et al. (1991) Prevalence and Significance of Antibodies to Hepatitis C Virus among Saudi Hemodialysis Patients. Journal of Medical Virology, 35, 155-159.
[9] Al-Nasser, M.N., Al-Mugeiren, M.A., Assuhaimi, S.A., Obineche, E., Onwabalili, J., et al. (1992) Seropositivity to Hepatitis C Virus in Saudi Hemodialysis Patients. Vox Sanguinis, 62, 94-97.
[10] Al-Furayh, O., Sobh, M. and Buali, A.R. (1992) Hepatitis C Virus Infection in Chronic Hemodialysis Patients, a Clinicopathologic Study. Nephrology Dialysis & Transplant, 7, 327-332.
[11] Al-Jiffri, A.M., Fadag, R.B., Ghabrah, T.M. and Ibrahim, A. (2007) Hepatitis C Virus Infection among Patients on Hemodialysis in Jeddah: A Single Center Experience. Saudi Journal of Kidney Disease & Transplantation, 14, 84-89.
[12] Al-Muhanna FA (1995). Hepatitis C virus infection among hemodialysis patients in the Eastern region of Saudi Arabia. Saudi Journal of Kidney Disease & Transplantation,6, 125-127.
[13] Al-Shohaib, S.S., Abdelaal, M.A., Zawawi, T.H., Abbas, F.M., Shaheen, F.A., et al. (1995) The Prevalence of Hepatitis C Virus Antibodies among Hemodialysis Patients in Jeddah Area, Saudi Arabia. Saudi Journal of Kidney Disease & Transplantation, 6, 128-131.
[14] Bernieh, B., Allam, M., Halepota, A., Mohamed, A.O., Parkar, J., et al. (1995) Prevalence of Hepatitis C Virus Antibodies in Hemodialysis Patients in Madinah Al-Munawarah. Saudi Journal of Kidney Disease & Transplantation, 6, 132-135.
[15] Shaheen, F.A.M., Huraib, S.O. and Al-Rasheed, R. (1995) Prevalence of Hepatitis C Antibodies among Hemodialysis Patients in the Western Province of Saudi Arabia. Saudi Journal of Kidney Disease & Transplantation, 6, 136-139.
[16] Al Meshari, K., Al Ahdal, M., Alfurayh, O., Ali, A., De Vol, E. and Kessie, G. (1995) New Insights into Hepatitis C Virus Infection of Hemodialysis Patients: The Implications. American Journal of Kidney Disease, 25, 572-578.
[17] Alfurayh, O., Sabeel, A., Al Ahdal, M.N., Almeshari, K., Kessie, G., et al. (2000) Hand Contamination with Hepatitis C Virus in Staff Looking after Hepatitis C-Positive Hemodialysis Patients. American Journal of Nephrology, 20, 103-106.
[18] Shobokshi, O.A., Serebour, F.E., Skakni, L, Al-Saffy, Y.H. and Ahdal, M.N. (1999) Hepatitis C Genotypes and Subtypes in Saudi Arabia. Journal of Medical Virology, 58, 44-48.<44::AID-JMV6>3.0.CO;2-U
[19] Al-Mugeiren, M., Al-Rasheed, S., Al-Salloum, A., El-Zouki, A., Al-Sohaibani, M., et al. (1996) Hepatitis C Virus Infection in Two Groups of Paediatric Patients: One Maintained on Haemodialysis and the Other on Continuous Ambulatory Peritoneal Dialysis. Annals of Tropical Paediatrics, 16, 335-339.
[20] Soyannwo, M.A., Khan, N., Kommajosyula, S., Abdel Rahman, A.R., Khadaji, M., et al. (1996) Hepatitis C Antibodies in Haemodialysis and Pattern of End-Stage Renal Failure in Gassim, Saudi Arabia. African Journal of Medicine 7 Medical Sciences, 25, 13-22.
[21] White, A.G., Leheny, W., Kuchipudi, P., Varghese, M., Al Riyami, H., et al. (1999) Histocompatibility Antigens in Omanis: Comparison with Other Gulf Populations and Implications for Disease Association. Annals of Saudi Medicine, 19, 193-196.
[22] Sheth, K.V., Edwards, J.A. and Godwin, J.T. (1987). Study of the HLA Gene and Antigen Frequency from a Saudi Arabian Hospital. Tissue Antigens, 25, 156-162.
[23] Hadhoud, A., Abdulaziz, A.M., Menawi, L.A., Shaheen, F.A., Abdulghaffar, A., et al. (2003) The Relationship between HLA Typing and HCV Infection and Outcome of Renal Transplantation in HCV Positive Patients. Experimental & Clinical Transplantation, 1, 19-25.
[24] Fitzmaurice, K., Petrovic, D., Ramamurthy, N., Simmons, R., Merani, S., et al. (2011) Molecular Footprints Reveal the Impact of the Protective HLA-A*03 Allele in Hepatitis C Virus Infection. Gut, 60, 1563-1571.
[25] Cangussu, L.O., Teixeira, R., Campos, E.F., Rampim, G.F., Mingoti, S.A., et al. (2011) HLA Class II Alleles and Chronic Hepatitis C Virus Infection. Scandanavian Journal of Immunology, 74, 282-287.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.